周五盘中，眼科医疗技术公司Glaukos Corp（股票代码：GKOS）股价出现显著上涨，涨幅达7.21%，引起投资者广泛关注。
这一涨势可能与Stephens & Co.最新发布的分析报告有关。该机构维持了对Glaukos的"买入"评级，尽管将目标价从140.00美元下调至115.00美元。分析师的持续看好态度似乎增强了投资者的信心，推动了股价上涨。
Glaukos Corp是一家专注于开发创新眼科治疗方案的公司，主要针对青光眼、角膜疾病和视网膜疾病。公司recently推出的iDose TR药物植入物，旨在为青光眼患者提供长期持续的眼内治疗，显示了公司在眼科医疗技术领域的创新能力。此外，Glaukos还提供多种微创手术器械产品，如iStent、iStent inject W和iStent infinite，进一步巩固了其在眼科医疗器械市场的地位。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.